203569-23-7

Basic information

• Product Name: Pyridine, 2-Methyl-6-(1H-pyrazol-3-yl)-
• Synonyms: Pyridine, 2-Methyl-6-(1H-pyrazol-3-yl)-;2-Methyl-6-(1H-pyrazol-3-yl)-Pyridine;2-Methyl-6-(1H-pyrazol-3-yl)pyridine 97%
• CAS NO: 203569-23-7
• Molecular Formula: C₉H₉N₃
• Molecular Weight: 159.18786
• Mol File: 203569-23-7.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Pyridine, 2-Methyl-6-(1H-pyrazol-3-yl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Pyridine, 2-Methyl-6-(1H-pyrazol-3-yl)-(203569-23-7)
• EPA Substance Registry System: Pyridine, 2-Methyl-6-(1H-pyrazol-3-yl)-(203569-23-7)

Safety Data

• Hazardous Substances Data: 203569-23-7(Hazardous Substances Data)

Usage

General Description

Pyridine, 2-Methyl-6-(1H-pyrazol-3-yl)- is a complex organic compound that incorporates both pyridine and pyrazole moieties. It is a chemical compound with the formula C10H11N3. It falls under the category of heterocyclic aromatic compounds, having both cyclic and aromatic properties due to alternate single and double bonds in its structure. Pyrazole, a constituent in the compound, is a class of organic compounds having a five-membered ring with three carbon atoms and two nitrogen atoms. This chemical compound is used in a variety of industrial applications, and its properties are well-studied in organic chemistry owing to its unique structure and potential for various reactions.

Upstream product

• 1122-62-9 2-acetylpyridine 
• 854923-64-1 (E)-3-(dimethylamino)-1-(6-methylpyridin-2-yl)prop-2-en-1-one 
• 79571-43-0 3-dimethylamino-1-(6-methylpyridine-2-yl)prop-2-en-1-one 
• 6940-57-4 2-acetyl-6-methylpyridine 
• 5315-25-3 2-bromo-6-methylpyridine 

Relevant articles and documents

GALNAC-TGFBR1 INHIBITOR CONJUGATES FOR THE TREATMENT OF LIVER DISEASES

Conjugates comprising GalNAc moiety and a TGFβR1 inhibitor are provided. In some embodiments, the conjugates are useful for the treatment of viral infections, cancer, and fibrosis.

Discovery and in vitro and in vivo profiles of N-ethyl-N-[2-[3-(5-fluoro-2-pyridinyl)-1H-pyrazol-1-yl]ethyl]-2-(2H-1,2,3-triazol-2-yl)-benzamide as a novel class of dual orexin receptor antagonist

Orexins play an important role in sleep/wake regulation, and orexin receptor antagonists are a focus of novel therapy for the treatment of insomnia. We identified 27e (TASP0428980) as a potent dual orexin receptor antagonist through the systematic modification of our original designed lead A. We demonstrated the potent sleep-promoting effects of 27e at ip dose of 3 mg/kg in a rat polysomnogram study. 27e exhibited relatively short half-life profiles in rats and dogs. Furthermore, accumulating evidence regarding ADME profiles indicates that the predicted human half-life of 27e should be 1.2-1.4 h. These data indicated that 27e has a short-acting hypnotic property, suggesting that 27e might be useful for treating primary insomnia while exhibiting a low risk of next-day residual somnolence. Thus, 27e and its related compounds should be further evaluated to enable advancement to clinical trials.